Related Experiment Video
Updated: Jun 15, 2025
A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
Published on: January 29, 2021
Cellular, Structural Basis, and Recent Progress for Targeting Murine Double Minute X (MDMX) in Tumors
Qikun Yin1, Yuemiao Hu1, Zhiwen Dong1
1School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China.
Targeting the oncoprotein murine double minute X (MDMX) shows promise for cancer treatment. This review explores MDMX structure and ligands, focusing on differences with MDM2 to enable specific MDMX targeting.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Murine double minute X (MDMX) is an oncoprotein that negatively regulates the tumor suppressor p53, promoting tumorigenesis.
- High MDMX expression in various tumors makes it a potential therapeutic target for cancer treatment.
- Structural similarity between MDMX and MDM2 presents a significant challenge for developing selective MDMX inhibitors.
Purpose of the Study:
- To review the structure, distribution, and regulation of MDMX.
- To summarize the structural features and structure-activity relationships (SARs) of MDMX ligands.
- To highlight the structural differences between MDMX and MDM2 to facilitate the development of specific MDMX-targeting strategies.
Main Methods:
- Literature review focusing on MDMX and MDM2 structure, function, and ligand interactions.
- Comparative analysis of structural features and SARs between MDMX and MDM2 ligands.
- Identification of key differences to inform the design of selective therapeutic agents.
Main Results:
- Detailed overview of MDMX's biological roles and regulatory mechanisms.
- Comprehensive summary of known MDMX ligands and their SARs.
- Identification of specific structural distinctions between MDMX and MDM2 that can be exploited for targeted therapy.
Conclusions:
- Developing specific MDMX inhibitors is crucial for effective cancer therapy.
- Understanding the structural differences between MDMX and MDM2 is key to achieving therapeutic selectivity.
- This review provides a foundation for designing novel strategies to specifically target MDMX in cancer treatment.
